Developing small-molecule treatments to reverse the debilitating impact of degenerative diseases
Frequency is pioneering a new category in regenerative medicine, developing small-molecule therapeutics to selectively activate progenitor cells already present within the body to create healthy, functional tissues.
Sensorineural Hearing Loss (SNHL)
Stage: Phase 2
Double-blind, placebo-controlled, multi-center study designed to evaluate the efficacy of FX-322 individuals with noise induced and sudden SNHL, aged 18 – 65.
Stage: Phase 1
Single-blind, placebo-controlled, multicenter study to evaluate the safety of FX-345 in individuals with adult-onset acquired SNHL, aged 18-67
Study enrolling 36 subjects, first subject dosed December 2022
Our Program for Sensorineural Hearing Loss
Advancing FX-322 into a Phase 2b clinical study for the most common form of hearing lossLearn More
Our Program for Multiple Sclerosis
Developing medicines that activate the cells needed to restore myelin, potentially reversing damage done by multiple sclerosisLearn More